Breaking News
Odometers Rolled ForwardStarlink Spy Network: Is Elon Musk Setting Up A Secret Backchannel At GSA?
The Worst New "Assistance Technology"
Vows to kill the Kennedy clan, crazed writings and eerie predictions...
Top Tech News
Scientists reach pivotal breakthrough in quest for limitless energy:
Kawasaki CORLEO Walks Like a Robot, Rides Like a Bike!
World's Smallest Pacemaker is Made for Newborns, Activated by Light, and Requires No Surgery
Barrel-rotor flying car prototype begins flight testing
Coin-sized nuclear 3V battery with 50-year lifespan enters mass production
BREAKTHROUGH Testing Soon for Starship's Point-to-Point Flights: The Future of Transportation
Molten salt test loop to advance next-gen nuclear reactors
Quantum Teleportation Achieved Over Internet For The First Time
Watch the Jetson Personal Air Vehicle take flight, then order your own
Microneedles extract harmful cells, deliver drugs into chronic wounds
Experimental cancer drug that targets common genetic fault can shrink tumours...
An experimental cancer drug that targets a common genetic fault has been shown to shrink tumours by up to 67 per cent in just six weeks.
Scientists tested their newly developed anti-cancer drug AMG 510 on four patients, two of whom saw their tumours shrink. It did not work for the others.
In studies on mice, the treatment helped to shrink, and in some cases eradicate, the growing tumours.
The daily pill works by turning 'off' the KRAS gene. Mutated forms of the genes are permanently trapped 'on', causing cancerous cells to multiply.
This abnormal activity fuels the development of up to 50 per cent of lung cancers, as well as some pancreatic and bowel cancers.
The pharmaceutical company described their findings as a 'milestone' for patients with cancer KRAS-mutant cancers.
The research was led by by pharmaceutical company Amgen Research, based in Thousand Oaks, California.
The findings, published in Nature, are the first to report the effects of inhibiting KRAS with a drug.